Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity Than Competitors NEW YORK, NY--(Marketwired - May 2, 2013) -  Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced,...

Nuvilex, Inc. Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard NEW YORK, NY--(Marketwired - Apr 29, 2013) - While many biotech and pharmaceutical companies are designing one drug after another to address specific health problems, Nuvilex, Inc. (OTCQB: NVLX) is...

Nuvilex, Inc. Price Valuation Justifies Investors' Confidence in Biotech NEW YORK, NY--(Marketwired - Apr 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology firm quietly going about its business in Silver Spring, Maryland. The company is currently...

Nuvilex, Inc. Expects its Technology Can Start to Change Life for Diabetics NEW YORK, NY--(Marketwired - Apr 8, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) started its diabetes studies, it was likely well known then that while its late-stage pancreatic cancer trials are front...

Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It NEW YORK, NY--(Marketwire - Mar 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its future might be anything but small. As the company...